adamantane has been researched along with sq 109 in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (23.08) | 29.6817 |
| 2010's | 27 (69.23) | 24.3611 |
| 2020's | 3 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Coward, L; Gorman, GS; Jia, L; Noker, PE; Tomaszewski, JE | 1 |
| Coward, L; Gorman, GS; Jia, L; Noker, PE; Protopopova, M; Tomaszewski, JE | 1 |
| Chen, P; Einck, L; Gearhart, J; Nacy, CA; Protopopova, M | 1 |
| Einck, L; Nacy, CA; Nikonenko, BV; Protopopova, M; Samala, R | 1 |
| Spigelman, MK | 1 |
| Zhang, Y | 1 |
| Mancera, RL; Rivers, EC | 1 |
| Li, W; Liu, Y; Luo, H; Meng, Q; Yao, Q; Zhang, W | 1 |
| Govender, P; Govender, T; Kruger, HG; Maguire, GE; Onajole, OK; van Helden, PD; Wiid, I | 1 |
| Andries, K; Einck, L; Nacy, CA; Reddy, VM | 1 |
| Nuermberger, EL; Spigelman, MK; Yew, WW | 1 |
| Ginsberg, AM | 1 |
| Alland, D; Arora, K; Barnes, SW; Barry, CE; Boshoff, HI; Fischer, E; Kastrinsky, DB; Nair, V; Tahlan, K; Walker, JR; Wilson, R | 1 |
| Campbell, S; Dubuisson, T; Einck, L; Jakubiec, W; Ladukto, L; Nacy, CA; Reddy, VM; Wallis, RS | 1 |
| Campbell, S; Jakubiec, W; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS | 1 |
| Axelson, J; Cao, R; Li, K; Lin, FY; Liu, YL; Oldfield, E; Pang, R; Zhu, W | 1 |
| Andries, K; Barry, CE; Nacy, CA; Protopopova, M; Sacksteder, KA | 1 |
| Cole, ST; Hartkoorn, RC; Lechartier, B | 1 |
| Einck, L; Makobongo, MO; Merrell, DS; Peek, RM | 1 |
| Elamin, AA; Singh, M; Stehr, M | 1 |
| Jeong, BH; Koh, WJ; Kwon, YS | 1 |
| Crans, DC; Crick, DC; Fontes, FL; Franzblau, SG; Grzegorzewicz, AE; Jackson, M; Jones, V; Lee, RE; Li, W; North, EJ; Upadhyay, A; Wang, Y | 1 |
| Chang, KC; Heyckendorf, J; Lange, C; Olaru, ID; von Groote-Bidlingmaier, F; Yew, WW | 1 |
| Benaim, G; de Carvalho, TM; de Souza, W; Docampo, R; Galizzi, M; Gonzalez-Pacanowska, D; Guo, RT; Hernandez-Rodriguez, V; Huang, G; Lameira, L; Li, K; Li, Q; Oldfield, E; Shang, N; Urbina, JA; Veiga-Santos, P | 1 |
| Aarnoutse, RE; Boeree, MJ; Dawson, R; Diacon, AH; du Bois, J; Gillespie, SH; Heinrich, N; Henne, S; Hoelscher, M; Horwith, G; Nacy, CA; Narunsky, K; Phillips, PP; Phipps, AJ; Rachow, A; Venter, A | 1 |
| Cole, ST; Dhar, N; Hartkoorn, RC; Lechartier, B; Sala, C; Vocat, A; Zhang, M | 1 |
| Diacon, AH; Donald, PR; Friedrich, SO; Kayigire, XA; van der Merwe, L | 1 |
| Chopra, S; Dasgupta, A; De Groote, MA; Soni, I | 1 |
| Bhakta, S; Brown, AK; Castagnolo, D; Dasugari, S; Evangelopoulos, D; Maitra, A; Manetti, F; McHugh, TD; Mortazavi, PN; Petricci, E; Scalacci, N; Twist, A | 1 |
| Benaim, G; García-García, V; Oldfield, E | 1 |
| Aarnoutse, R; Boeree, MJ; Charalambous, S; Churchyard, G; Colbers, A; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; Heinrich, N; Henne, S; Hoelscher, M; Hunt, RD; Kibiki, GS; Manyama, C; Mekota, A; Minja, LT; Mpagama, SG; Mtafya, B; Narunsky, K; Ntinginya, NE; Phillips, PPJ; Rehal, S; Reither, K; Sanne, I; Semvua, HH; van Balen, GP; Venter, A; Wallis, RS | 1 |
| Anastasiou, K; Foscolos, AS; Georgiadis, MO; Karalis, V; Kellici, T; Ladia, P; Lentzos, D; Mavromoustakos, T; Papanastasiou, I; Siamidi, A; Spaneas, D; Vlachou, M | 1 |
| Clemens, DL; Dillon, BJ; Ho, CM; Horwitz, MA; Lee, BY; Masleša-Galić, S; Nava, S; Silva, A | 1 |
| Cheng, X; Guddat, LW; Jiang, B; Jiang, H; Li, J; Liu, Z; Rao, Z; Wu, L; Yang, H; Yang, X; Yang, Y; Zhang, B; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Nair, SG; Patel, DB; Patel, HD; Rathwa, SK; Vasava, MS | 1 |
| Benaim, G; Galindo, I; Gil, Z; Martinez, JC; Martinez-Sotillo, N; Mejias, F; Oldfield, E; Pinto-Martinez, A | 1 |
| Borshchevskiy, V; Bukhdruker, S; Gilep, A; Grabovec, I; Grudinin, S; Gusach, A; Kadukova, M; Kavaleuski, A; Marin, E; Shabunya, P; Strushkevich, N; Varaksa, T | 1 |
| Guo, Y; Qiu, W | 1 |
12 review(s) available for adamantane and sq 109
| Article | Year |
|---|---|
New tuberculosis therapeutics: a growing pipeline.
Topics: Adamantane; Animals; Antitubercular Agents; Clinical Trials as Topic; Diamines; Diarylquinolines; Ethylenediamines; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Tuberculosis | 2007 |
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2007 |
SQ109.
Topics: Adamantane; Animals; Antitubercular Agents; Ethylenediamines; Humans; Treatment Outcome; Tuberculosis | 2008 |
New anti-tuberculosis drugs with novel mechanisms of action.
Topics: Adamantane; Animals; Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Quinolines; Structure-Activity Relationship; Tuberculosis, Pulmonary | 2008 |
Current development and future prospects in chemotherapy of tuberculosis.
Topics: Adamantane; Animals; Antitubercular Agents; Carbapenems; Clinical Trials as Topic; Diarylquinolines; Drug Delivery Systems; Ethylenediamines; Fluoroquinolones; Humans; Isonicotinic Acids; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Patient Compliance; Pyrroles; Quinolines; Rifamycins; Tuberculosis, Pulmonary | 2010 |
Drugs in development for tuberculosis.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Discovery; Ethylenediamines; Humans; Quinolines; Tuberculosis | 2010 |
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.
Topics: Adamantane; Animals; Antitubercular Agents; Drug Discovery; Drug Interactions; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Mice; Mycobacterium tuberculosis; Tuberculosis | 2012 |
Filling the pipeline - new drugs for an old disease.
Topics: Adamantane; Antitubercular Agents; Cyclic GMP-Dependent Protein Kinases; Diarylquinolines; Enzymes; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Molecular Targeted Therapy; Mycobacterium tuberculosis; Nitroimidazoles; Quantitative Structure-Activity Relationship | 2014 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Novel drugs against tuberculosis: a clinician's perspective.
Topics: Adamantane; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarylquinolines; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Nitroimidazoles; Oxazoles; Oxazolidinones; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria.
Topics: Adamantane; Aminopyridines; Anti-Bacterial Agents; Azepines; Benzamides; Clinical Trials as Topic; Diarylquinolines; Drug Discovery; Ethylenediamines; Fluoroquinolones; Humans; Minocycline; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Piperazines; Spiro Compounds; Thiazines; Tigecycline; Uridine | 2016 |
Development of new drug-regimens against multidrug-resistant tuberculosis.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Development; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Ethylenediamines; Humans; Isoniazid; Macrolides; Medication Adherence; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant | 2019 |
3 trial(s) available for adamantane and sq 109
| Article | Year |
|---|---|
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Therapy, Combination; Ethylenediamines; Female; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2015 |
Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments.
Topics: Adamantane; Antitubercular Agents; Bacterial Load; Benzophenoneidum; Colony Count, Microbial; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Fluorescent Dyes; Humans; Lipid Droplets; Microscopy, Fluorescence; Mycobacterium tuberculosis; Oxazines; Predictive Value of Tests; Rifampin; South Africa; Sputum; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2015 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Ethylenediamines; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Rifampin; South Africa; Tanzania; Tuberculosis, Pulmonary | 2017 |
24 other study(ies) available for adamantane and sq 109
| Article | Year |
|---|---|
Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.
Topics: Adamantane; Amino Acid Sequence; Antitubercular Agents; Databases, Genetic; Electrophoresis, Polyacrylamide Gel; Ethambutol; Ethylenediamines; Isoniazid; Molecular Sequence Data; Mycobacterium tuberculosis; Peptide Fragments; Peptide Mapping; Protein Hydrolysates; Proteome; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Trypsin | 2005 |
Interspecies pharmacokinetics and in vitro metabolism of SQ109.
Topics: Adamantane; Animals; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Blood Proteins; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Dogs; Enzyme Inhibitors; Ethylenediamines; Female; Humans; Male; Metabolic Clearance Rate; Mice; Mixed Function Oxygenases; Protein Binding; Rats; Rats, Inbred F344; Species Specificity; Tissue Distribution | 2006 |
Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.
Topics: Adamantane; Antitubercular Agents; Drug Resistance, Bacterial; Drug Synergism; Ethylenediamines; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin | 2006 |
Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.
Topics: Adamantane; Animal Experimentation; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Ethylenediamines; Lung; Mice; Mycobacterium tuberculosis; Treatment Outcome; Tuberculosis | 2007 |
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
Topics: Adamantane; Administration, Oral; Animals; Antitubercular Agents; Carbamates; Ethylenediamines; Prodrugs; Rats; Tissue Distribution | 2009 |
Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates.
Topics: Adamantane; Antitubercular Agents; Dose-Response Relationship, Drug; Ethylenediamines; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Stereoisomerism | 2010 |
In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Interactions; Ethylenediamines; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolines; Rifampin | 2010 |
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.
Topics: Acyltransferases; Adamantane; Aerobiosis; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Cell Wall; Chromatography, Thin Layer; Cord Factors; Drug Resistance, Bacterial; Ethylenediamines; Lipid Metabolism; Membrane Transport Proteins; Microbial Sensitivity Tests; Microscopy, Electron; Mutation; Mycobacterium tuberculosis; Mycolic Acids | 2012 |
SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.
Topics: Adamantane; Animals; Antitubercular Agents; Cell Line; Drug Interactions; Ethylenediamines; Macrophages; Mice; Microbial Viability; Mycobacterium tuberculosis; Oxazolidinones | 2012 |
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Time Factors | 2012 |
Head-to-head prenyl tranferases: anti-infective drug targets.
Topics: Adamantane; Bacterial Proteins; Crystallography, X-Ray; Enzyme Inhibitors; Ethylenediamines; Farnesyl-Diphosphate Farnesyltransferase; Models, Molecular; Phenyl Ethers; Quinuclidines; Staphylococcus aureus; Thiocyanates | 2012 |
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins | 2012 |
In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori.
Topics: Adamantane; Amoxicillin; Antitubercular Agents; Cell Membrane; Chloramphenicol; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Duodenal Ulcer; Duodenitis; Ethylenediamines; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Metronidazole; Microbial Sensitivity Tests; Microscopy, Electron; Stomach Ulcer | 2013 |
Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.
Topics: Adamantane; Anti-Bacterial Agents; Antitubercular Agents; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carrier Proteins; Cell Membrane; Cord Factors; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Membrane Proteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Mycobacterium smegmatis; Mycobacterium tuberculosis; Mycolic Acids; Phenylurea Compounds; Piperazines; Proton Ionophores; Pyrroles; Tuberculosis, Multidrug-Resistant; Valinomycin; Vitamin K 2 | 2014 |
SQ109, a new drug lead for Chagas disease.
Topics: Adamantane; Animals; Chagas Disease; Ethylenediamines; Hemolysis; Humans; In Vitro Techniques; LLC-PK1 Cells; Membrane Potential, Mitochondrial; Squalene; Sterols; Swine; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2015 |
Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Drug Discovery; Ethylenediamines; Genes, Bacterial; Luminescence; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazines; Oxazolidinones; Photorhabdus; Pyrazinamide; Rifamycins; Xanthenes | 2015 |
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
Topics: Adamantane; Antitubercular Agents; Carrier Proteins; Cell Line; Cell Survival; Computational Biology; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium; Mycobacterium tuberculosis; Pharmaceutical Preparations; Piperazines; Pyrroles; Structure-Activity Relationship | 2016 |
Inhibition of Leishmania mexicana Growth by the Tuberculosis Drug SQ109.
Topics: Adamantane; Animals; Antiprotozoal Agents; Antitubercular Agents; Calcium; Cell Line; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ethylenediamines; Inhibitory Concentration 50; Leishmania mexicana; Macrophages; Mice | 2016 |
In vitro Controlled Release of two new Tuberculocidal Adamantane Aminoethers from Solid Pharmaceutical Formulations (II).
Topics: Adamantane; Administration, Oral; Antitubercular Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Ethers; Ethylenediamines; Excipients; Hydrogen-Ion Concentration; Solubility; Tablets; Tuberculosis | 2017 |
Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.
Topics: Adamantane; Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Combinations; Ethylenediamines; Humans; Lung; Mice; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis | 2018 |
Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target.
Topics: Adamantane; Antitubercular Agents; Bacterial Proteins; Biological Transport; Drug Delivery Systems; Drug Design; Ethylenediamines; Humans; Membrane Proteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Phenylurea Compounds; Rimonabant; Tuberculosis | 2019 |
SQ109 inhibits proliferation of Leishmania donovani by disruption of intracellular Ca
Topics: Adamantane; Animals; Cell Proliferation; Chagas Disease; Cytoplasm; Ethylenediamines; Humans; Leishmania donovani; Leishmania mexicana; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages; Membrane Potential, Mitochondrial; Mitochondria; Trypanosoma cruzi | 2020 |
Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450.
Topics: Adamantane; Antitubercular Agents; Binding Sites; Cytochrome P-450 Enzyme System; Ethylenediamines; Hydroxylation; Molecular Docking Simulation; Mycobacterium tuberculosis; Protein Binding | 2020 |
Analysis of the oligomeric state of mycobacterial membrane protein large 3 and its interaction with SQ109 with native cell membrane nanoparticles system.
Topics: Adamantane; Bacterial Proteins; Carrier Proteins; Cell Membrane; Ethylenediamines; Lipids; Membrane Proteins; Membrane Transport Proteins; Mycobacterium; Nanoparticles | 2022 |